A Phase 2 interventional study of Recombinant Human Proteoglycan 4 and Vehicle Control in Sjögren's Syndrome, sponsored by Lubris Bio Pty Ltd. Recruiting at 7 sites in Australia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Lubris Bio Pty Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Sjogren's Syndrome with a site in Australia — 7 open to participants now, 11 under way, 6 of them phase 3. Sjogren's Syndrome · Australia.
Among the 18 studies in Sjogren's Syndrome with a site in Australia, this one is the 12th largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 3 of the 10 other live ones, and was the 13th registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →7 of the 18 studies in Sjogren's Syndrome with a site in Australia are open now. Recruiting first, the newest first:
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in Australia
Ages 18–75 · Healthy volunteers
Novartis Pharmaceuticals · Sites in Australia, United States, Canada and 6 more countries
Ages 18–100
Candid Therapeutics · Sites in Australia
Ages 18–65 · Healthy volunteers
Novartis Pharmaceuticals · Sites in Australia, United States, Austria and 17 more countries
Ages 18+
Xencor, Inc. · Sites in Australia
Ages 18–75 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 7
First in 2016; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 240 across the 18 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 18 have an industry lead sponsor. The 8 most frequent:
Lubris Bio Pty Ltd is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Lubris Bio Pty Ltd has 2 studies filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Sjogren's Syndrome with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07118241Lubris Bio Pty LtdA PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Sjogren's Syndrome with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren's related Dry Eye Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Are females of (those who are not surgically sterilized or for at least 1 year) who meet any one of the following conditions:
Are males with a female partner of child bearing potential where:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PBS Based Vehicle Control
Drug: Vehicle Control
rhPRG4 450ug/ml
Drug: Recombinant Human Proteoglycan 4
rhPRG4 450ug/ml
PBS based Vehicle Conrtol
To assess the efficacy of rhPRG4 by looking at the frequency of patients attaining complete resolution of total corneal staining with fluorescein (Oxford Scale) at Day 28
To assess the efficacy of rhPRG4 by looking at the frequency of patients attaining complete resolution of total corneal staining with fluorescein (Oxford Scale) at Day 28
Time frame: From baseline to the end of treatment at day 28
To assess the safety of rhPRG4 by observation of the severity of treatment-emergent adverse events for the study duration
To assess the safety of rhPRG4 by observation of the severity of treatment-emergent adverse events for the study duration
Time frame: From baseline to day 28
To assess the safety of rhPRG4 by observation of the change in BCVA over 28 days
To assess the safety of rhPRG4 by observation of the change in BCVA over 28 days
Time frame: From baseline to day 28
To assess the safety of rhPRG4 by observation of signs evaluated by slit lamp examination (SLE) (Meibomian glands, Eyelid Erythema, Eyelid Oedema, Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Hyperemia, Corneal transparency & Corneal neo
To assess the safety of rhPRG4 by observation of signs evaluated by slit lamp examination (SLE) (Meibomian glands, Eyelid Erythema, Eyelid Oedema, Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Hyperemia, Corneal transparency \& Corneal neovascularization)
Time frame: From baseline to day 28
To assess the safety of rhPRG4 by observation of intraocular pressure (IOP)
To assess the safety of rhPRG4 by observation of intraocular pressure (IOP)
Time frame: From baseline to day 28
To assess the efficacy of rhPRG4 using the total VAS score for dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia (anchors: none & severe) at Day 28
To assess the efficacy of rhPRG4 using the total VAS score for dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia (anchors: none \& severe) at Day 28
Time frame: From baseline to day 28
To assess the efficacy of rhPRG4 using the SANDE score compared to vehicle at Day 28
To assess the efficacy of rhPRG4 using the SANDE score compared to vehicle at Day 28
Time frame: From baseline to day 28
To assess the efficacy of rhPRG4 using the Oxford staining score, both per eye and as a total score per subject compared to vehicle at Day 28
To assess the efficacy of rhPRG4 using the Oxford staining score, both per eye and as a total score per subject compared to vehicle at Day 28
Time frame: From baseline to day 28
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.
Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's planned 15 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jul 2026 → Dec 2026 and completion Aug 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lubris Bio Pty Ltd